Alison Moskowitz, MD
Enriched profileAssociate Attending Physician · Memorial Sloan Kettering Cancer Center
Alison Moskowitz is Associate Attending Physician at Memorial Sloan Kettering Cancer Center. OpenAlex indexes 478 publications with 10,308 citations (h-index 50); ClinicalTrials.gov lists 16 registered studies with this person as an investigator.
Data verified 23 Oct 2026
Overview
Updated 25 Oct 2026
Alison J. Moskowitz is Associate Attending Physician at Memorial Sloan Kettering Cancer Center. The public record shows 478 publications with 10,308 citations (h-index 50), centered on Lymphoma Diagnosis and Treatment, Viral-associated cancers and disorders, Cutaneous lymphoproliferative disorders research. It also documents an investigator role on 16 registered clinical trials, industry payments reported by 14 companies.
- Most recent indexed publication: 2026 · Cancers
- Top research focus: Lymphoma Diagnosis and Treatment
- 16 registered trials on ClinicalTrials.gov
- Open Payments reporting from 14 companies
Generated from the cited public record · current as of 25 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 10 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 142.
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 25 Oct 2026
Listed as an investigator on 16 registered studies on ClinicalTrials.gov. The most recent:
- Ruxolitinib for the Treatment of T-Cell Large Granular Lymphocytic Leukemia
Sponsor: Jonathan Brammer
- A Study of Ruxolitinib and Duvelisib in People With Lymphoma
Sponsor: Memorial Sloan Kettering Cancer Center
Industry payments
Updated 25 Oct 2026
14 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Merck Sharp & Dohme LLCProgram year20252 payments
- Secura Bio, Inc.Program year20251 payment
- PFIZER INC.Program year20251 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
34.4%Kinase inhibitor13.4%Calquence49%Imbruvica26%Jakafi26%Part D<11 patientsPhosphatidylinositol-3-kinase (Pi3K) inhibitors10%Copiktra100%Part D<11 patients+ 2 more classes in this area
Metabolism & gastrointestinal
18.8%Corticosteroid11.9%Prednisone100%Part D≥18 patientsProton pump inhibitor6.9%Pantoprazole Sodium100%Part D≥11 patientsDermatology
15%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor15%Acyclovir100%Part D≥14 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Congress activity
Updated 25 Oct 2026
137 congress contributions (2014–2026) across AACR, ASCO, ASH, ASTRO per OpenAlex. The most recent:
- Efficacy and tolerability of duvelisib in relapsed/refractory peripheral T-cell lymphoma: A multicenter real-world analysis.
ASCO Annual Meeting
ASCO2026Co-author - Patient-Reported Outcomes during Radiotherapy for Mycosis Fungoides and Other Cutaneous Lymphomas
ASTRO Annual Meeting
ASTRO2026Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 25 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Phase II Trial of Nivolumab Plus Doxorubicin, Vinblastine, Dacarbazine as Frontline Therapy in Older Adults With Hodgkin Lymphoma.
Journal of clinical oncology
Clinical Trial2025
Most-cited works
by citation count (OpenAlex)- 01
- 02Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome)Article382 citations2014
- 03Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome)Article347 citations2014
- 04
- 05
Network
Updated 25 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 25 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/alison-moskowitz-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
Mentions by others
where others cite or feature them- Other
mskcc.org/cancer-care/doctors/alison-moskowitz
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 25 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- MD
Albert Einstein College of Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗
- Residency: Internal Medicine
Columbia University Medical Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗ - Fellowship: Hematology/Medical Oncology
Memorial Sloan Kettering Cancer Center/Weill Cornell Medical College
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗
Editorial & leadership roles
journal and society appointments- Scientific Advisory Board Member
Lymphoma & CLL Hub
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →lymphomahub.com ↗ - Member
American Society of Clinical Oncology (ASCO)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗ - Member
American Society of Hematology (ASH)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Howard Scher, MD
Memorial Sloan Kettering Cancer Center
Robert Motzer, MD
Memorial Sloan Kettering Cancer Center
Charles Sawyers, MD
Memorial Sloan Kettering Cancer Center
Mark Kris, MD
Memorial Sloan Kettering Cancer Center
Seth Steinberg, PhD
National Cancer Institute (NCI)
Gilles Salles
Memorial Sloan Kettering Cancer Center
Thomas Witzig, MD
Mayo Clinic
Wyndham Wilson, MD
National Cancer Institute (NCI)